The Pretransplantation Assessment of Mortality (PAM) score is a risk score for mortality after allogeneic hematopoietic SCT (HSCT). Ethnicity is a genetically determined factor that correlated with immune-mediated outcomes of allogeneic HSCT. We evaluated the predictive value of the PAM score for transplant outcome in 276 Japanese populations in which transplantrelated complications occur less frequently than Caucasians. The PAM score effectively risk-stratified these patients for survival; overall survival (OS) at 2 years was 100%, 80.2%, 49.4%, and 13.9% in the categories 1, 2, 3, and 4, respectively, showing a clear distinction of OS by categories (Po0.001). In addition, the PAM score is useful for the prediction of transplant outcomes both in patients with standard-risk underlying diseases and those with high-risk diseases. The PAM score developed in Caucasian populations is thus useful in non-Caucasian populations.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) is a curative but toxic treatment for hematological disorders. Its indication is expanding with the greater use of alternative donors and stem cell sources, such as PBSC and umbilical cord blood. Moreover, the advent of non-myeloablative conditioning regimens has led to an increasing use of transplantation for older, having comorbidities, and more heavily pretreated patients. In these patients, estimation of benefits and risks of this high-risk procedure is particularly crucial for decision making.
Recent studies have made great efforts to develop reliable and reproducible predictive models in this setting: The Pretransplantation Assessment of Mortality (PAM) score was developed at the Fred Hutchinson Cancer Research Center (FHCRC) to predict all-cause mortality within 2 years after allogeneic HSCT. 1 It is calculated by using multiple transplant-related variables, including patients' ages, donor type and the conditioning regimen as well as patients' comorbidities. However, predictive values of the PAM score remain unclear at other centers, in particular outside the Western countries. 2, 3 It has been well recognized that ethnicity is one of the factors, which may affect the transplant outcome. 4 --6 In this study, we evaluated whether the PAM score could be predictive for transplant outcome also in Japanese patients.
PATIENTS AND METHODS Patients
The medical records of 276 patients who underwent their first allogeneic HSCT at the Kyushu University Hospital or Hamanomachi Hospital between January 2004 and March 2009 were reviewed. Primary diseases included myelodysplastic syndrome/AML; n ¼ 125, CML; n ¼ 12, ALL; n ¼ 43, malignant lymphoma (ML; n ¼ 76), aplastic anemia (n ¼ 10), solid tumors (n ¼ 4) and others (n ¼ 6). A total of 148 cases were categorized into the standard-risk (SR) group defined as follows: acute leukemia (AML or ALL) in CR; CML in chronic phase; myelodysplastic syndrome classified as refractory anemia or refractory cytopenia with multilineage dysplasia, ML in at least PR and non-malignant hematological disorders. All others (n ¼ 128) were defied as high-risk (HR) group. This study was approved by the Institutional Review Board.
Transplantation procedures
A total of 180 patients had received myeloablative preparative regimens, TBI/CY (n ¼ 142), BU/CY (n ¼ 31) or others (n ¼ 7). The remaining 96 cases had received fludarabine (Flu)-based reduced intensity conditioning regimen with either CY (n ¼ 4), BU (n ¼ 71) or melphalan (n ¼ 21; Table 1 ). Low-dose TBI (2 --4 Gy) and alemtuzumab were included into the above reduced intensity conditioning regimen in 76 and 3 patients, respectively. The sources of stem cells were PBSC from a related donor (n ¼ 53), BM from a related (n ¼ 23) or unrelated donor (n ¼ 161) or cord blood (n ¼ 39). HLA matching varied from haploidentical (3/6) to identical (6/6). GVHD prophylaxis was calcineurin inhibitor (CI) plus either short-term MTX (n ¼ 268) or mycophenolate mofetil (n ¼ 7), and CI alone (n ¼ 1). A total of 22 patients had a previous history of autologous PBSCT. Risk status assessment PAM score components, including age at transplantation, disease risk, donor type, conditioning regimen and liver (serum level of alanine aminotransferase), kidney (serum level of creatinine), and lung (one second forced expiratory volume and diffusing capacity for carbon monoxide) function, were collected and scored as originally described 1 using automatic calculation system on web site (http://cdsweb.fhcrc.org/pam/).
The variables used to calculate the European Group for Blood and Marrow Transplantation (EBMT) risk score were age, interval from diagnosis to transplant, disease status, donor --recipient sex match and donor type. The risk-score for an individual patient is simply the sum of the scores of each risk factor, as originally reported.
Statistical analysis
The main aim of this retrospective analysis was to assess the predictive value of the PAM score on 2-year overall survival (OS) in allogeneic HSCT recipients. OS was defined as the time from the day of stem cell infusion to death with any cause. The probability of OS was estimated using Kaplan --Meier curves and compared using the log-rank tests. For univariate comparisons, we examined variables, including age, sex, underlying diseases, disease status, conditioning regimen, stem cell source, HLA matching, GVHD prophylaxis and prior HSCT using w 2 test or Mann --Whitney test. P-values o0.05 were considered to indicate statistical significance. The diagnostic reliability of these models was compared by using the c-statistics. All statistical analyses used SPSS 17.0 program (SPSS Japan Inc., Tokyo, Japan) or SAS ver9.2.
RESULTS

Patient characteristics
There were 155 men and 121 women with a median age of 47. 5 years. Patients' characteristics are listed in Table 1 . A total of 148 patients (54%) had SR diseases and 128 (46%) had HR diseases at Validation of PAM score in non-Caucasians Y Mori et al transplantation. As compared with SR disease patients, patients with HR disease were less likely to have ALL (P ¼ 0.025), but more likely to receive CBT (P ¼ 0.089) or reduced intensity conditioning regimen (P ¼ 0.016). HSCT recipients for HR disease were significantly associated with HLA-mismatched donor (P ¼ 0.042) as a reflection of more frequent use of CBT in HR patients than SR patients.
PAM score Among 276 patients, 13 (5%), 44 (16%), 182 (66%) and 37 (13%) patients were classified into categories 1, 2, 3 and 4, respectively, based on the categorization of PAM score. The median PAM score was 26 (range, 11 --38) and the distribution of the score was shown in Figure 1a . Because disease status was one of the factors for scoring, patients with HR disease tended to have higher PAM scores compared with those with SR disease; numbers of patients fit into categories 1, 2, 3 and 4 were 0 (0%), 4 (3%), 92 (72%) and 32 (25%) in HR patients, whereas 13 (9%), 40 (27%), 90 (61%) and 5 (3%) in SR patients (Po0.001). Hepatic dysfunction was the most common comorbidity (44 out of 276, 16%) in our cohort (Figure 1b) . The frequency of other comorbidities were as follows: 10% with low one second forced expiratory volume, 10% with low diffusing capacity for carbon monoxide and 3% with increased serum creatinine level, consistent with the original study at FHCRC. 1 The proportion of patients with low one second forced expiratory volume was significantly greater in patients with HR disease than those with SR disease (14.1% vs 6.8%; P ¼ 0.05, Figure 1b ). Univariate analysis revealed that these components of PAM score, except for hepatic dysfunction, were independent prognostic factors in this study (data not shown).
Probability of 2-year OS by PAM score categories The median follow-up of surviving patients is 45.4 months (range, 10.3 --81.5 months); OS at 2 years was 51.8% (Figure 2a ). There was a stepwise relationship between PAM score category and survival; The 2-year probability of OS was 100%, 80.2%, 49.4% and 13.9% in patients with category 1, 2, 3 and 4, respectively (Po0.001), showing a clear distinction of OS by categories (Figure 2b ). Although this study was designed to evaluate 2-year survival, it appeared that PAM score was also predictive for long-term survival beyond 2 years after transplant.
During the observation period, 64 patients (23.2%) died of disease progression; 0%, 9.1%, 26.4% and 32.4% in category 1, 2, 3 and 4, respectively, whereas 73 (26.4%) patients died of non-relapse mortality (NRM); 0%, 11.4%, 26.4% and 54.1% in category 1, 2, 3 and 4, respectively. The most common causes of NRM were infections (n ¼ 27) and GVHD (n ¼ 21).
We next compared the predictive value of the PAM score with that of the EBMT risk score, which is another well-established prognostic model for transplant outcome. 7, 8 Among 268 patients, 0 (0%), 30 (11%), 47 (18%), 61 (23%), 78 (29%), 46 (17%) and 6 (2%) patients were classified into risk score 0, 1, 2, 3, 4, 5 and 6 --7, respectively ( Table 1) . The distribution of patients was relatively skewed into higher risk group, when compared with previous reports, 7, 8 mainly due to more advanced disease status and older age in our cohort. Higher risk score in the EBMT risk model was associated with HR patients (Po0.001; Table 1 ) and higher PAM score (data not shown). We found that the EBMT risk score was also useful for a risk stratification in our cohort (Po0.001, shown in Figure 2c ). However, its predictive value for transplant outcome determined by c-statistics was slightly lower than that of the PAM score (0.63 vs 0.70; Table 2 ).
Impact of PAM scores on survival according to disease status We then evaluated the impact of PAM scores on OS in HR patients (n ¼ 128) and SR patients (n ¼ 148) separately. At 2 years, patients with SR diseases had significantly better OS compared with those with HR diseases (64.2% vs 37.3%, Po0.001). For patients with SR diseases, 2-year OS was 100%, 80.8%, 56.0% and 0% in categories 1, 2, 3 and 4, respectively (Figure 3a) , with a statistically significant difference among 4 groups (Po0.001). There were also statistical or marginal differences either in category 1 vs 2 (P ¼ 0.10), category 2 vs 3 (P ¼ 0.007) or in category 3 vs 4 (Po0.001).
In patients with HR diseases, no case was classified into category 1. In all, 2-year OS was 75.0%, 43.0% and 16.2% in category 2, 3 and 4 groups, respectively (Po0.001; Figure 3b ). In this subgroup analysis, there was no significant difference between categories 2 and 3 (P ¼ 0.23), possibly due to the low numbers of patients categorized in category 2, whereas there was a significant difference between categories 3 and 4 (Po0.001).
Impact of PAM scores on survival according to graft source We next evaluated predictive values of PAM scores for transplant outcome after CBT (n ¼ 39) vs BMT/PBSCT (n ¼ 237). CBT was preferentially performed in HR patients than in SR patients due to rapid availability of cord blood and less stringent requirement for HLA matching. CBT recipients had more HR diseases (59.0% vs 44.3%, P ¼ 0.09), higher PAM score (mean score; 28.3 vs 25.4, proportion of patients classified into category 3 or 4; 92.3% vs 77.2%, P ¼ 0.07) and worse 2-year OS (35.8% vs 54.3%, P ¼ 0.05) when compared with BMT/PBSCT recipients (data not shown).
No CBT recipients were classified into category 1, and 2-year OS in category 2, 3 and 4 was 50%, 40.9% and 0%, respectively. PAM score could not distinguish the outcome of patients in category 2 from that in category 3 (P ¼ 0.36; Figure 3c ). In contrast, the PAM score was useful for the prediction of outcome among BMT/PBSCT recipients; 2-year OS was 100%, 81.7%, 51.0% and 16.7% in category 1, 2, 3 and 4, respectively (Po0.001). There were also statistical differences in category 2 vs 3 (P ¼ 0.001) and category 3 vs 4 (Po0.001) or a trend in category 1 vs 2 (P ¼ 0.10; Figure 3d ).
Impact of PAM score according to underlying diseases In this study, 2-year OS of patients with ML was inferior to that of non-ML patients, possibly because approximately half of ML cases were adult T-cell leukemia/lymphoma (ATL), which had a very poor prognosis. 9 Thus, we further performed subgroup analysis in patients with ATL and those with other diseases.
Characteristics of patients with ATL (n ¼ 35) were comparable to those without ATL (n ¼ 241) except for having an older age (median; 55 vs 45, P ¼ 0.003). Significantly inferior 2-year OS was observed in patients with ATL compared with those without ATL (28.7% vs 55.1%, P ¼ 0.001; data not shown). ATL patients in category 1, 2, 3 and 4 groups had 100%, 25%, 29.3% and 0% of 2-year OS, respectively ( Figure 3e) ; The PAM score could not distinguish transplant outcome of category 2 patients from that of category 3 patients (P ¼ 0.54).
In contrast, the PAM score effectively risk-stratified patients with other diseases for survival: 2-year OS in category 1, 2, 3 and 4 were 100%, 81.8%, 52.6% and 15.7%, respectively (Po0.001; Figure 3f ).
There was also a statistically significant difference in OS between category 2 and 3 (P ¼ 0.001).
Modification of categorization of PAM score Although this study demonstrated that the PAM score was predictive of transplant outcome in our cohort, there was a skewed distribution of patients with the majority of patients squeezed into categories 2 and 3. This makes the PAM score less useful in the clinical setting and may be related to difference in mortality in each category between our study and the original study. We therefore made a modification of categorization of PAM score to subdivide patients more equally into each category. Patients were classified into low-(score 8 --19), intermediate- (20 --25) , high-(26 --30) or very-high-(31 --50) risk category. With this stratification, 30 (11%), 80 (29%), 129 (47%) and 37 (13%) patients were categorized in low, intermediate, high and very high risk group, respectively (Table 2) . A 2-year OS was significantly different between the 4 groups (92.4%, 67.5%, 43.7% and 14.0%, respectively; Po0.001; Figure 4a ), which was comparable to that in the original report. Predicitive value of the PAM score with modified categorization determined by c-statistics was better than that of the original PAM score (0.74 vs 0.70; Table 2 ). Notably, this flexible PAM score showed a powerful predictive value for transplant outcome both in patients with SR and HR diseases (Figures 4b and c) .
DISCUSSION
Reliable pretransplant estimation of the transplant outcome is very important for therapeutic decision making. One of these indices is the hematopoietic cell transplantation comorbidity index (HCT-CI), 10 which is a modification of the Charslon comorbidity index 11 and primarily designed to predict NRM after HSCT. Its usefulness for the estimation of OS as well as NRM has been demonstrated in various situations.
2,12 --14 EBMT risk score, originally defined as a risk score for patients with CML, has been confirmed its applicability in other hematological disorders. 8 The risk score was based on five criteria, disease status, patients' age, donor type, time from diagnosis to HSCT and donor --recipient sex combination, whereas no comorbidity covariate was considered for the scoring. A modified EBMT risk score omitted the variable time from diagnosis to HSCT from the analysis because it strongly correlated with disease stage and stem cell source, resulting in multiple sources of bias. 15, 16 The PAM score has been recently established for the estimation of 2-year all cause mortality; the PAM score includes both comorbidities and pretransplant variables such as disease status, type of donors and conditioning regimens. PAM score is highly predictive for transplant outcome in retrospective analyses of large numbers of patients at FHCRC. 1, 17 However, predictive values of the PAM score remain unclear at other centers. 2, 3 As ethnicity is an additional important determinant of immune-mediated outcomes of allogeneic HSCT, 6 we examined prognostic values of the PAM score in a genetically homogeneous Japanese population. We found that the PAM score was also predictive for transplant outcome in this population. Its predictive value was higher than that of EBMT risk score at least in this study, and was comparable to that of the original report from FHCRC. 1 However, 2-year OS of each category is somewhat different from those from FHCRC. One of the important differences in the variables for scoring between FHCRC studies and our study is intensity of reduced intensity conditioning regimen. FHCRC mostly used 200 cGy TBI ± fludarabine, 1 while a more intensified fludarabine-based regimen was used in this study. Thus, patients receiving reduced intensity conditioning had a high score in the 'conditioning regimen' variable in our study, and majority of these patients were classified into category 3.
For the improvement of prognostic predictive value, modified categorizations of HCT-CI and PAM score have been tested. A 
